Advertisement

Dissolution Testing

  • Sau Lawrence Lee
  • Andre S. Raw
  • Lawrence Yu

Ever since dissolution was known to have a significant effect on bioavailability and clinical performance, dissolution analysis of pharmaceutical solids has become one of the most important tests in drug product development and manufacturing, as well as in regulatory assessment of drug product quality. Not only can dissolution testing provide information regarding the rate and extent of drug absorption in the body, it can also assess the effects of drug substance biopharmaceutical properties and formulation principles on the release properties of a drug product. Nevertheless, despite the wide use of dissolution testing by the pharmaceutical industry and regulatory agencies, the fundamentals and utilities of dissolution testing are still not fully understood. The objective of this chapter is to provide a concise review of dissolution methods that are used for quality control (QC) and bioavailability assessment, highlight issues regarding their utilities and limitations, and review challenges of improving some of these current dissolution methods, particularly those used for assessing in vivo drug product performance. In this chapter, we first provide some background information on dissolution, including the significance of dissolution in drug absorption, theories of dissolution, and factors affecting dissolution testing. Second, we examine the current roles of dissolution testing. Third, we evaluate the utilities and limitations of dissolution as a QC tool under the current industry setting. Finally, we conclude this chapter by discussing the biopharmaceutics classification system (BCS) and biorelevant dissolution methods.

Keywords

Dissolution Rate Dosage Form Drug Product Drug Substance Dissolution Medium 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Amidon, G.L., Lennern äs, H., Shah, V.P., and Crison, J.R. (1995). A theoretical basis for a biopharmaceutics drug classification: the correlation of in vivo drug product dissolution and in vivo bioavailability. Pharm. Res. 12:413-420.CrossRefPubMedGoogle Scholar
  2. Armenante, P., and Muzzio, F. (2005). Inherent method variability in dissolution testing: the effect of hydrodynamics in the USP II Apparatus. A Technical Report Submitted to the Food and Drug Administration.Google Scholar
  3. Ashby, L.J., Beezer, A.E., and Buckton, G. (1989). In vitro dissolution testing of oral controlled release preparations in the presence of artificial foodstuffs. I. Exploration of alternative methodology: microcalorimetry. Int. J. Pharm. 51:245-251.Google Scholar
  4. Bandelin, F.J. (1990). Compressed Tablets by Wet Granulation. In: Lieberman, H.A., Lachman, L., and Schwartz, J.B. (eds.), Pharmaceutical Dosage Forms: Tablets, Volume 1. Marcel Dekker, Inc., New York, pp. 199-302.Google Scholar
  5. Brown, C.K., Chokshi, H.P., Nickerson, B., Reed, R.A., Rohrs, B.R., and Shah, P.A. (2004). Acceptable analytical practices for dissolution testing of poorly soluble compounds. Pharm. Tech. 56-65.Google Scholar
  6. Brunner, E. (1904). Reaktionsgeschwindigkeit in heterogenen Systemen. Z. Phys. Chem. 43:56-102.Google Scholar
  7. Brunner, L., and Tolloczko, S. (1900). Über die Aufl ösungsgeschwindingkeit fester K örper. Z. Physiol. Chem. 35:283-290.Google Scholar
  8. Borst, I., Ugwu, S., and Beckett, A.H. (1997). New and extended application for USP drug release Apparatus 3. Dissolut. Technol. 1-6.Google Scholar
  9. Carey, M.C., and Small, D.M. (1972). Micelle formation by bile salts. Physical-chemical and thermodynamic considerations. Arch. Intern. Med. 130:506-527.CrossRefPubMedGoogle Scholar
  10. Christiansen, P. (1968). The incidence of achlorhydria in healthy subjects and patients with gastrointestinal diseases. Scan. J. Gastroenterol. 3:497-508.CrossRefGoogle Scholar
  11. Corrigan, O.I. (1985). Mechanisms of dissolution of fast release solid dispersions. Drug Dev. Ind. Pharm. 11:697-724.CrossRefGoogle Scholar
  12. Danckwerts, P.V. (1951). Significance of liquid-film coefficients in gas absorption. Ind. Eng. Chem. 43:1460-1467.CrossRefGoogle Scholar
  13. Davenport, H.W. (1982). Physiology of the Digestive Tract, 5th ed. Year Book Medical Publishers, Inc., Chicago.Google Scholar
  14. Dressman, J.B. (2000). Dissolution testing of immediate-release products and its applica-tion to forecasting in vivo performance. In: Dressman, J.B., and Lennern äs, H. (eds.), Oral Drug Absorption: Prediction and Assessment, Volume 106. Marcel Dekker, Inc., New York, pp. 155-181.Google Scholar
  15. Dressman, J.B., Berardi, R.R., Dermentzoglou, L.C., Russell, T.L., Schmaltz, S.P., Barnett, J.L., and Jarvenpaa, K.M. (1990). Upper gastrointestinal (GI) pH in young healthy men and women. Pharm. Res. 7:756-761.CrossRefPubMedGoogle Scholar
  16. Dressman, J.B., Amidon, G.L., Reppas, C., and Shah, V.P. (1998). Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm. Res. 15:11-22.CrossRefPubMedGoogle Scholar
  17. Efentakis, M., and Dressman, J.B. (1998). Gastric juice as a dissolution medium: surface tension and pH. Eur. J. Drug Metab. Pharmacokinet. 23:97-102.PubMedGoogle Scholar
  18. FDA (1997a). Center for Drug Evaluation and Research, Guidance for industry. Dissolution testing of immediate release solid oral dosage forms.Google Scholar
  19. FDA (1997b). Center for Drug Evaluation and Research, Guidance for industry. Extended release oral dosage forms: development, evaluation, and application of in vitro/in vivo correlations.Google Scholar
  20. FDA (2000). Center for Drug Evaluation and Research, Guidance for industry. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system.Google Scholar
  21. Finholt, P. (1974). Influence of formulation on dissolution rate. In Leeson, L.J., and Carstensen, J.T. (eds.), Dissolution Technology, American Pharmaceutical Association, Washington, DC, pp. 106-146.Google Scholar
  22. Finholt, P., and Solvang, S. (1968). Dissolution kinetics of drugs in human gastric juice -the role of surface tension. J. Pharm. Sci. 57:1322-1326.CrossRefPubMedGoogle Scholar
  23. Finholt, P., Gundersen, H., Smit, A., and Petersen, H. (1978). Surfactant tension of human gastric juice. Medd. Norsk. Farm. Selsk. 41:1-14.Google Scholar
  24. Fordtran, J.S., and Locklear, T.W. (1966). Ionic constituents and osmolality of gastric and small-intestinal fluids after eating. Am. J. Dig. Dis. 11:503-521.CrossRefPubMedGoogle Scholar
  25. Fraser, E.J., Leach, R.H., and Poston, J.W. (1972). Bioavailability of digoxin. Lancet 2:541.CrossRefPubMedGoogle Scholar
  26. Gandhi, R., Lal Kaul, C., and Panchagnula, R. (1999). Extrusion and spheronization in the development of oral controlled-release dosage forms. Pharm. Sci. Technol. Today 4:160-170.CrossRefPubMedGoogle Scholar
  27. Gordon, M.S., and Rudraraju, V.S. (1993). Effect of the mode super disintegrant incorpo-ration on dissolution in wet granulated tablets. J. Pharm. Sci. 82:220-226.CrossRefPubMedGoogle Scholar
  28. Greenwood, D.E. (1994). Small intestinal pH and buffer capacity: implication for dis-solution of ionizable compounds. Doctoral Dissertation. The University of Michigan, Ann Arbor.Google Scholar
  29. Hanson, W.A. (1982). Handbook of Dissolution Testing, Volume 49. Pharmaceutical Tech-nology Publications, Oregon.Google Scholar
  30. Higuchi, T. (1961). Rate of release of medicaments from ointment bases containing drugs in suspension. J. Pharm. Sci. 50:874-875.CrossRefPubMedGoogle Scholar
  31. Howard, S.A., Mauger, J.W., Khwangsopha, A., and Pasquerelli, D.A. (1979). Tablet position and basket type effects in spin-filter dissolution device. J. Pharm. Sci. 68: 1542-1545.CrossRefPubMedGoogle Scholar
  32. Klein, S. (2005). Biorelevant dissolution test methods for modified release dosage forms. Doctoral Thesis. Johann Wolfgang Goethe University Frankfurt, Shaker-Verlag.Google Scholar
  33. Levy, G., Leonards, J.R., and Procknal, J.A. (1965). Development of in vitro dissolution tests which correlate quantitatively with dissolution rate-limited drug absorption in man. J. Pharm. Sci. 54:1719-1722.CrossRefGoogle Scholar
  34. Loftsson, T., Hreinsd óttir, D., and M ásson, M. (2005). Evaluation of cyclodextrin solubi-lization of drugs. Inter. J. Pharm. 302:18-28.CrossRefGoogle Scholar
  35. Macheras, P., Koupparis, M., and Apostelelli, E. (1987). Dissolution of four controlledrelease theophylline formulations in milk. Int. J. Pharm. 36:73-79.CrossRefGoogle Scholar
  36. Mauger, J.W., Howard, S.A., and Khwangsopha, A. (1979). Hydrodynamic characterization of a spin-filter dissolution device. J. Pharm. Sci. 68: 1084-1087.CrossRefPubMedGoogle Scholar
  37. McCarthy, L.G., Bradley, G., Sexton, J.C., Corrigan, O.I., and Healy, A.M. (2004). Computational fluid dynamics modeling of the paddle dissolution apparatus: agitation rate, mixing patterns, and fluid velocities. AAPS PharmSciTech. 5:1-10.CrossRefGoogle Scholar
  38. Meyer, J.H., Elashoff, J., Porter-Fink, V., Dressman, J., and Amidon, G.L. (1988). Human postprandial gastric emptying of 1-3 millimeter spheres. Gastroenterology 94: 1315-1325.PubMedGoogle Scholar
  39. Miller, D.A., McConville, J.T., Yang, W., Williams III, R.O., and McGinity J.W. (2006). Hot-melt extrusion for enhanced delivery of drug particles. J. Pharm. Sci. 96:361-376.CrossRefGoogle Scholar
  40. Mithani, S.D., Bakatselou, V., TenHoor, C.N., and Dressman, J.B. (1996). Estimation of the increase in solubility of drugs as a function of bile salt concentration. Pharm. Res. 13:163-167.CrossRefPubMedGoogle Scholar
  41. Moore, J.G., Christian, P.E., and Coleman, R.E. (1981). Gastric emptying of varying meal weight and composition in man. Evaluation by dual liquid- and solid-phase isotopic method. Dig. Dis. Sci. 26:16-22.CrossRefPubMedGoogle Scholar
  42. Nelson, E. (1957). Solution rate of theophylline salts and effects from oral administration. J. Am. Pharm. Assoc. 46:607-614.Google Scholar
  43. Nernst, W.(1904). Theorie der reaktionsgeschwindigkeit in heterogenen systemen. Z. Physiol. Chem. 47:52-55.Google Scholar
  44. Ovesen, L., Bendtsen, F., Tage-Jensen, U., Pedersen, N.T., Gram, B.R., and Rune, S.L. (1986). Intraluminal pH in the stomach, duodenum, and proximal jejunum in nor-mal subjects and patients with exocrine pancreatic insufficiency. Gastroenterology 90: 958-962.PubMedGoogle Scholar
  45. Peck, G.E., Baley, G.J., McCurdy, V.E., and Banker, G.S. (1989). Tablet Formulation and Design. In: Lieberman, H.A., Lachman, L., and Schwartz, J.B. (eds.), Pharmaceutical Dosage Forms: Tablets, Volume 1. Marcel Dekker, Inc., New York, pp. 73-130.Google Scholar
  46. Pinnamaneni, S., Das, N.G., and Das, S.K. (2002). Formulation approaches for orally administered poorly soluble drugs. Pharmazie 57:291-300.PubMedGoogle Scholar
  47. Rekhi, G.S., Eddington, N.D., Fossler, M.J., Schwartz, P., Lesko, L.J., and Augsburger, L.L. (1997). Evaluation of in vitro release rate and in vivo absorption characteristics of four metoprolol tartrate immediate-release tablet formulations. Pharm. Dev. Technol. 2:11-24.CrossRefPubMedGoogle Scholar
  48. Russell, T.L., Berardi, R.R., Barnett, J.L., Dermentzoglou, L.C., Jarvenpaa, K.M., Schmaltz, S.P., and Dressman, J.B. (1993). Upper gastrointestinal pH in seventy-nine healthy, elderly North American men and women. Pharm. Res. 10:187-196.CrossRefPubMedGoogle Scholar
  49. Schott, H., Kwan, L.C., and Feldman, S. (1982). The role of surfactants in the release of very slightly soluble drugs from tablets. J. Pharm. Sci. 71:1038-1045.CrossRefPubMedGoogle Scholar
  50. Shah, V.P., Konecny, J.J., Everett, R.L., McCullough, B., Noorizadeh, A.C., and Skelly, J.P. (1989). In vitro dissolution profile of water-insoluble drug dosage forms in the presence of surfactants. Pharm. Res. 6:12-18.Google Scholar
  51. Shangraw, R. F. (1990). Compressed Tablets by Direct Compression. In: Lieberman, H.A., Lachman, L., and Schwartz, J.B. (eds.), Pharmaceutical Dosage Forms: Tablets, Volume 1, Marcel Dekker, Inc., New York, pp. 195-246.Google Scholar
  52. Sievert, B., and Siewert, M. (1998). Dissolution tests for ER products. Dissolut. Technol. 5:1-7.Google Scholar
  53. Stavchansky, R., and McGinity, J. (1989). Bioavailability and Tablet Technology. In: Lieberman, H.A., Lachman, L., and Schwartz, J.B. (eds.), Pharmaceutical Dosage Forms: Tablets, Volume 2, Marcel Dekker, Inc., New York, pp. 349-553.Google Scholar
  54. Swanepoel, E., Liebenberg, W., and de Villiers, M.M. (2003). Quality evaluation of generic drugs by dissolution test: changing the USP dissolution medium to distinguish between active and non-active mebendazole polymorphs. Eur. J. Pharm. Biopharm. 55:345-349.CrossRefPubMedGoogle Scholar
  55. Wagner, J.G. (1970). Rate of dissolution in vivo and in vitro, part II. Drug Intell. Clin. Pharm. 4:32.Google Scholar
  56. Yu, L.X. (1999). An integrated absorption model for determining causes of poor oral drug absorption, Pharm. Res. 16:1883-1887.CrossRefPubMedGoogle Scholar
  57. Yu, L.X., and Amidon, G.L. (1999). Analytical solutions to mass transfer. In Amidon, G.L., Lee, P.I., and Topp, E.M. (eds.), Transport Processes in Pharmaceutical Systems, Volume 102, Marcel Dekker, Inc., New York, pp. 23-54.Google Scholar
  58. Yu, L.X., Wang, J.T., and Hussain, A.S. (2002). Evaluation of USP Apparatus 3 for Dissolution Testing of Immediate-Release Products. AAPS PharmSci. 4:1-5.CrossRefGoogle Scholar
  59. Zhang, H., and Yu, L.X. (2004). Dissolution testing for solid oral drug products: theoretical consideration. Am. Pharm. Rev. 26-31.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Sau Lawrence Lee
    • 1
  • Andre S. Raw
    • 1
  • Lawrence Yu
    • 1
  1. 1.Food and Drug AdministrationCenter for Drug Evaluation & ResearchRockvilleUSA

Personalised recommendations